无细胞系统:为加速发现和生产基于的抗生素的理想平台
Hyeongwoo Park1, Haneul Jin2, Dayeong Kim2
1School of Interdisciplinary Bioscience and Bioengineering (I-Bio), Pohang University of Science and Technology, Pohang 37673, Republic of Korea.
International journal of molecular sciences
|August 29, 2024
概括
无细胞系统加速了基于的抗生素 (PBA) 的发现和生产,为抗生素耐药性提供了有前途的解决方案. 这些系统增强了新型抗微生物 (AMP) 和其模仿物的识别和表征.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 基于的抗生素 (PBA),包括抗菌 (AMP),表现出多样化的生物活性.
- 传统的抗生素因病原体耐药性和狭窄的疗效而面临限制.
- 高通量测序和生物信息学有助于发现新的PBA产生酶和途径.
研究的目的:
- 审查无细胞系统 (CFS) 在加速PBA发现和生产中的应用.
- 突出CFS作为克服传统抗生素局限性的解决方案.
- 展示CFS在开发有效抗抗生素耐药感染的药物的作用.
主要方法:
- 适应无细胞系统以控制体外转录和翻译.
- 高通量测序和生物信息学的整合,用于酶和途径的识别.
- 审查最近的例子,证明CFS在PBA研究中的实用性.
主要成果:
- CFS简化了新型PBA的识别,表征,选择和生产.
- CFS 提供对生物过程的精确控制,以有效开发药物.
- CFS促进了对抗耐药性病原体有效的新抗菌剂的获取.
结论:
- 无细胞系统是推动基于的抗生素研究的强大平台.
- 共同抗生素耐药性提供了一种可行的策略,以应对抗生素耐药性日益增长的威胁.
- 进一步开发CFS可以扩大抗菌剂的武器库.
更多相关视频
08:46Cell-Free Production of Proteoliposomes for Functional Analysis and Antibody Development Targeting Membrane Proteins
Published on: September 22, 2020
3.8K
07:35Rapid, Enzymatic Methods for Amplification of Minimal, Linear Templates for Protein Prototyping using Cell-Free Systems
Published on: June 14, 2021
2.7K
相关概念视频
Production of Antibiotics
285
Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...
285
Production of Pharmaceuticals
100
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
100
